Parthenolide, a natural inhibitor of nuclear factor-κB, inhibits lung colonization of murine osteosarcoma cells

Clinical Cancer Research

Volumn 13, Issue 1, 2007, Pages 59-67

  Kishida, Yuki ^a   Yoshikawa, Hideki ^a   Myoui, Akira ^a,b  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PARTHENOLIDE; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; LUNG METASTASIS; MALE; MOUSE; NONHUMAN; OSTEOSARCOMA; OSTEOSARCOMA CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION, NEOPLASTIC; LUCIFERASES; MALE; MICE; MICE, INBRED C3H; NEOPLASM METASTASIS; NF-KAPPA B; OSTEOSARCOMA; PROTEIN BINDING; SESQUITERPENES;

EID: 33846272165     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-1559     Document Type: Article

References (41)

1. Whelan JS. Osteosarcoma. Eur J Cancer 1997;33:1611-8; discussion 8-9.
2. Asai T, Tomita Y, Nakatsuka S, et al. VCP (p97) regulates NFκB signaling pathway, which is important for metastasis of osteosarcoma cell line. Jpn J Cancer Res 2002;93:296-304.
3. Asai T, Ueda T, Itoh K, et al. Establishment and characterization of a murine osteosarcoma cell line (LM8) with high metastatic potential to the lung. Int J Cancer 1998;76:418-22.
4. Thanos D, Maniatis T. NF-κB: a lesson in family values. Cell 1995;80:529-32.
5. Baldwin AS, Jr. The NF-κB and IκB proteins: new discoveries and insights. Annu Rev Immunol 1996;14:649-83.
6. Hansen SK, Nerlov C, Zabel U, et al. A novel complex between the p65 subunit of NF-κB and c-Rel binds to a DNA element involved in the phorbol ester induction of the human urokinase gene. EMBO J 1992;11:205-13.
7. Yokoo T, Kitamura M. Dual regulation of IL-1β-mediated matrix metalloproteinase-9 expression in mesangial cells by NF-κB and AP-1. Am J Physiol 1996;270:F123-30.
8. Yoshida S, Ono M, Shono T, et al. Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor α-dependent angiogenesis. Mol Cell Biol 1997;17:4015-23.
9. Meyskens FL, Jr., Buckmeier JA, McNulty SE, Tohidian NB. Activation of nuclear factor-κB in human metastatic melanoma cells and the effect of oxidative stress. Clin Cancer Res 1999;5:1197-202.
10. Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet RJ, Jr., Sledge GW, Jr. Constitutive activation of NF-κB during progression of breast cancer to hormone-independent growth. Mol Cell Biol 1997;17:3629-39.
11. Duffey DC, Chen Z, Dong G, et al. Expression of a dominant-negative mutant inhibitor-κBα of nuclear factor-κB in human head and neck squamous cell carcinoma inhibits survival, proinflammatory cytokine expression, and tumor growth in vivo. Cancer Res 1999;59:3468-74.
12. Fujioka S, Sclabas GM, Schmidt C, et al. Function of nuclear factor κB in pancreatic cancer metastasis. Clin Cancer Res 2003;9:346-54.
13. Huang S, DeGuzman A, Bucana CD, Fidler IJ. Level of interleukin-8 expression by metastatic human melanoma cells directly correlates with constitutive NF-κB activity. Cytokines Cell Mol Ther 2000;6:9-17.
14. Huang S, Pettaway CA, Uehara H, Bucana CD, Fidler IJ. Blockade of NF-κB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene 2001;20:4188-97.
15. Murphy JJ, Heptinstall S, Mitchell JR. Randomised double-blind placebo-controlled trial of fever few in migraine prevention. Lancet 1988;2:189-92.
16. Schinella GR, Giner RM, Recio MC, Mordujovich de Buschiazzo P, Rios JL, Manez S. Anti-inflammatory effects of South American Tanacetum vulgare. J Pharm Pharmacol 1998;50:1069-74.
17. Miglietta A, Bozzo F, Gabriel L, Bocca C. Microtubule-interfering activity of parthenolide. Chem Biol Interact 2004;149:165-73.
18. Zhang S, Ong CN, Shen HM. Critical roles of intracellular thiols and calcium in parthenolide-induced apoptosis in human colorectal cancer cells. Cancer Lett 2004;208:143-53.
19. Wen J, You KR, Lee SY, Song CH, Kim DG. Oxidative stress-mediated apoptosis. The anticancer effect of the sesquiterpene lactone parthenolide. J Biol Chem 2002;277:38954-64.
20. Sumner H, Salan U, Knight DW, Hoult JR. Inhibition of 5-lipoxygenase and cyclo-oxygenase in leukocytes by feverfew. Involvement of sesquiterpene lactones and other components. Biochem Pharmacol 1992;43:2313-20.
21. Patel NM, Nozaki S, Shortle NH, et al. Paclitaxel sensitivity of breast cancer cells with constitutively active NF-κB is enhanced by IκBα super-repressor and parthenolide. Oncogene 2000;19:4159-69.
22. Sweeney CJ, Mehrotra S, Sadaria MR, et al. The sesquiterpene lactone parthenolide in combination with docetaxel reduces metastasis and improves survival in a xenograft model of breast cancer. Mol Cancer Ther 2005;4:1004-12.
23. Andela VB, Schwarz EM, Puzas JE, O'Keefe RJ, Rosier RN. Tumor metastasis and the reciprocal regulation of prometastatic and antimetastatic factors by nuclear factor κB. Cancer Res 2000;60:6557-62.
24. Huang S, Robinson JB, Deguzman A, Bucana CD, Fidler IJ. Blockade of nuclear factor-κB signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8. Cancer Res 2000;60:5334-9.
25. Huang S, DeGuzman A, Bucana CD, Fidler IJ. Nuclear factor-κB activity correlates with growth, angiogenesis, and metastasis of human melanoma cells in nude mice. Clin Cancer Res 2000;6:2573-81.
26. Ko HM, Seo KH, Han SJ, et al. Nuclear factor κB dependency of platelet-activating factor-induced angiogenesis. Cancer Res 2002;62:1809-14.
27. Loercher A, Lee TL, Ricker JL, et al. Nuclear factor-κB is an important modulator of the altered gene expression profile and malignant phenotype in squamous cell carcinoma. Cancer Res 2004;64:6511-23.
28. Huber MA, Azoitei N, Baumann B, et al. NF-κB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression, J Clin Invest 2004;114:569-81.
29. Pan Q, Bao LW, Merajver SD. Tetrathiomolybdate inhibits angiogenesis and metastasis through suppression of the NFκB signaling cascade. Mol Cancer Res 2003;1:701-6.
30. Nakshatri H, Rice SE, Bhat-Nakshatri P. Anti-tumor agent parthenolide reverses resistance of breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand through sustained activation of c-Jun N-terminal kinase. Oncogene 2004;23:7330-44.
31. Malaguarnera U. Implications of apoptosis regulators in tumorigenesis. Cancer Metastasis Rev 2004;23:367-87.
32. Evan GI, Vousden KH. Proliferation, cell cycle, and apoptosis in cancer. Nature 2001;411:342-8.
33. Wells A. Tumor invasion: role of growth factor-induced cell motility. Adv Cancer Res 2000;78:31-101.
34. Yousefi S, Conus S, Simon HU. Cross-talk between death and survival pathways. Cell Death Differ 2003;10:861 -3.
35. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS, Jr. NF-κB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and C-IAP2 to suppress caspase-8 activation. Science 1998;281:1680-3.
36. Kim JH, Liu L, Lee SO, Kim YT, You KR, Kim DG. Susceptibility of cholangiocarcinoma cells to parthenolide-induced apoptosis. Cancer Res 2005;65:6312-20.
37. Liu CA, Wang MJ, Chi CW, Wu CW, Chen JY. Rho/Rhotekin-mediated NF-κB activation confers resistance to apoptosis. Oncogene 2004;23:8731-42.
38. Luzzi KJ, MacDonald IC, Schmidt EE, et al. Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am J Pathol 1998;153:865-73.
39. Weis S, Cui J, Barnes L, Cheresh D. Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis. J Cell Biol 2004;167:223-9.
40. Curry EA III, Murry DJ, Yoder C, et al. Phase I dose escalation trial of feverfew with standardized doses of parthenolide in patients with cancer. Invest New Drugs 2004;22:299-305.
41. Scian MJ, Stagliano KE, Anderson MA, et al. Tumor-derived p53 mutants induce NF-κB2 gene expression. Mol Cell Biol 2005;25:10097-110.